Alnylam Pharmaceuticals Stock Price - ALNY

0.41 (0.32%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-4.31 -3.27% 127.59 127.34 132.595 131.01 131.90 00:00:01
Bid Price Ask Price Spread Spread % News
118.00 135.00 17.00 12.59% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10,714 610,916 $ 128.96 $ 78,781,229 768,726 67.55 - 151.84
Last Trade Time Type Quantity Stock Price Currency
17:18:32 formt 100 $ 128.00 USD

Alnylam Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 14.65B 114.82M 82.91M $ 219.75M $ - -8.15 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Alnylam Pharmaceuticals News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALNY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week134.59139.19127.34135.37576,224-7.00-5.2%
1 Month142.58149.24126.24138.48650,999-14.99-10.51%
3 Months97.02151.8484.97124.24822,76330.5731.51%
6 Months121.66151.8484.97121.52745,4125.934.87%
1 Year69.25151.8467.55103.68716,66158.3484.25%
3 Years72.17153.98560.2799.98893,63655.4276.79%
5 Years128.58153.98531.3885.92915,263-0.99-0.77%

Alnylam Pharmaceuticals Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Your Recent History
Alnylam Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200606 08:48:39